ARCA biopharma, Inc, a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced that a comparative analysis of primary endpoint data from four betablocker trials was presented at the American College of Cardiology 58th Annual Scientific Session.

Results of the analysis, which compared all-cause mortality in participants in the COPERNICUS, MERIT-HF, CIBIS-II and BEST trials, suggest that differences in survival associated with betablocker treatment observed in clinical trials may be significantly influenced by inclusion of varying geographic populations (U.S. vs. Rest of World, or ROW) and that genetic diversity should be considered in the relevance of cardiovascular trials and interpretation of results. Large randomized, controlled trials have shown that beta-blockers reduce mortality by 34 to 35 per cent in heart failure patients with moderate to severe systolic dysfunction. The majority of patients enrolled in these trials were from outside the US. In contrast, the Beta-Blocker Evaluation of Survival Trial (BEST), the only intention-to-treat mortality trial which enrolled almost exclusively US patients, showed a 13 per cent reduction in all-cause mortality.

The magnitude of the effect on survival of beta-blocker therapy was either reduced (HR 0.80) or neutral (HR 1.05) in large US populations included in COPERNICUS and MERIT-HF, respectively. These effects are more comparative to BEST trial results with bucindolol in US patients. The Very Favorable genotype subgroup in BEST showed significantly improved mortality reduction compared to other beta-blockers. Such findings suggest that differences in beta-blocker survival benefit observed in clinical trials may be significantly influenced by inclusion of varying geographic populations. Genetic diversity should be considered in the relevance of cardiovascular trials and interpretation of results.

BEST included a prospectively-designed DNA substudy that identified a subgroup of approximately 47 per cent of participants who had the "Very Favorable" response genotype (beta1-adrenergic receptor 389 Arginine homozygous). This genotype subgroup of BEST was compared to the overall study cohorts. Comparisons were not prospectively defined at the time of the randomized trials. There is no adjustment for differences in baseline characteristics of the trial populations. The beta1-adrenergic receptor 389 Arginine/Glycine polymorphism is known to be influenced by racial differences that vary in European versus American populations, and other adrenergic receptor polymorphisms that could influence beta-blocker response also exhibit racial differences in allele frequencies.

Results of the analysis showed that Gencaro treatment in the Very Favorable genotype subgroup of BEST patients in the US resulted in a 44 per cent reduction in all-cause mortality, a 51 per cent reduction in cardiovascular mortality, a 49 per cent reduction in mortality plus cardiac transplant, a 38 percent reduction in mortality and heart failure hospitalizations, a 37 per cent reduction in heart failure progression, a 40 percent reduction in heart failure hospitalizations, a 52 per cent reduction in heart failure hospitalization days and 65 per cent reduction in total myocardial infarctions in heart failure patients.

"Geographically distinct populations can have different genetic profiles that can affect the safety and efficacy of drugs and devices," said Dr Christopher O'Connor, professor of medicine in the Division of Cardiology, chief of the Division of Clinical Pharmacology in the Department of Medicine, and director of the Duke Heart Failure Program at Duke University Medical Center. "Our comparative analysis investigated whether or not improvement in survival was different due to enrollment of ex-U.S. participants. Our findings revealed that differences in beta blocker survival benefit observed in clinical trials may be significantly influenced by inclusion of varying geographic populations. Therefore, we believe it is important to consider genetic diversity when interpreting clinical trial results."

ARCA biopharma is dedicated to developing and commercializing genetically targeted therapies for heart failure and other cardiovascular disease.